CN | EN
Development Strategy
Collaborations
Innovation Driven,BioCity has established a rich and potential Best-in-Class pipelines targeting therapeutic areas including oncology and Nephropathy.
As a fast-growing clinical-stage biopharmaceutical company with core competitiveness from project establishment to translational medicine and clinical development ,
BioCity is willing to collaborate with its partners to provide patients
with new therapeutic drugs and improve their quality of life.
Partner
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
Members of BD Team
 CBO Dr. Kaan Certel
kaan.certel@biocitypharma.com
  Dr. Connie Liu
connie.liu@biocitypharma.com
  Dr. Duan Wang
duan.wang@biocitypharma.com
  Dr. Andrew Wang
andrew.wang@biocitypharma.com